Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of NRX Pharmaceuticals Inc (NASDAQ: NRXP) was $2.63 for the day, down -5.40% from the previous closing price of $2.78. In other words, the price has decreased by -$5.40 from its previous closing price. On the day, 1.33 million shares were traded.
Ratios:
Our analysis of NRXP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.22 and its Current Ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on April 02, 2025, initiated with a Buy rating and assigned the stock a target price of $18.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 17 ’24 when Javitt Jonathan C bought 40,000 shares for $1.17 per share. The transaction valued at 46,800 led to the insider holds 84,634 shares of the business.
Stock Price History:
Over the past 52 weeks, NRXP has reached a high of $6.01, while it has fallen to a 52-week low of $1.10. The 50-Day Moving Average of the stock is 26.81%, while the 200-Day Moving Average is calculated to be 31.12%.
Shares Statistics:
A total of 17.12M shares are outstanding, with a floating share count of 14.34M. Insiders hold about 17.08% of the company’s shares, while institutions hold 13.28% stake in the company.
Earnings Estimates
A comprehensive evaluation of NRX Pharmaceuticals Inc (NRXP) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.36 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$0.4 and -$0.4 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is $0.5, with 1.0 analysts recommending between $0.5 and $0.5.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $13.5M. There is a high estimate of $13.5M for the next quarter, whereas the lowest estimate is $13.5M.
Based on 3 analysts’ estimates, the company’s revenue will be $107.58M in the next fiscal year. The high estimate is $180.3M and the low estimate is $42.43M.
